Secarna Pharmaceuticals and Orbit Discovery partner to develop peptide-conjugated targeted ASO therapeutics.

Secarna Pharmaceuticals and Orbit Discovery partner to develop peptide-conjugated targeted antisense oligonucleotide (ASO) therapeutics, expanding Secarna's capabilities in targeted ASOs beyond antibodies and sugar molecules. The collaboration leverages Orbit's expertise in peptide discovery and its bead-based peptide display engine for the identification, screening, and selection of cyclic peptides, potentially offering new treatment options for a wider range of diseases.

May 28, 2024
7 Articles

Further Reading